Texas is currently home to 4883 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/24/2025
Locations: Investigative Site US032, Dallas, Texas
Conditions: Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/24/2025
Locations: Investigative Site US260, Cypress, Texas
Conditions: Hidradenitis Suppurativa
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
Recruiting
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/24/2025
Locations: Arlington Center for Dermatology ( Site 0045), Arlington, Texas
Conditions: Hidradenitis Suppurativa
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Recruiting
This is a phase 1, first-in-human, open-label, dose-escalation study of XB628, a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Exelixis Clinical Site #2, San Antonio, Texas
Conditions: Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/24/2025
Locations: Elligo Clinical Research Center, Austin, Texas
Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/24/2025
Locations: Elligo Clinical Research Center, Austin, Texas
Conditions: Obesity
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Recruiting
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Texas Oncology Tyler, Tyler, Texas
Conditions: CLL, Chronic Lymphocytic Leukemia
Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC
Recruiting
This study examines a patient population with a non-healing, non-infected venous leg ulcer (VLU) having adequate arterial perfusion with confirmed venous reflux. It is hypothesized that weekly applications of the human placental allograft BioREtain® Amnion Chorion (BR-AC) applied to a non-healing VLU will result in a higher proportion of wounds showing complete healing within 12 weeks of initiating therapy, compared to standard care alone. This study has a crossover period, where subjects on st... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Site 03, Fort Worth, Texas
Conditions: Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis, Venous Reflux
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
Recruiting
The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).
Gender:
ALL
Ages:
Between 18 years and 105 years
Trial Updated:
07/24/2025
Locations: Heart Hospital of Austin, Austin, Texas
Conditions: Aortic Stenosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
Recruiting
This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Site Number - 1017, Colleyville, Texas
Conditions: Rheumatoid Arthritis
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
Recruiting
The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: R & H Clinical Research-777 S Fry Rd, Katy, Texas
Conditions: Sjögren's Syndrome
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
Recruiting
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma. The goal of Phase 2 of this clinical research study is to learn if the recommended Phase 2 dose of ivonescimab found in Phase 1 can help to control the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Glioblastoma